Dashboard
Viking Therapeutics, Inc.
VKTXNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16Trial initiationClinicalTrials.gov
Phase 3 SUNRISE 1 trial (NCT07868835) of oral VK2735 for weight management updated to recruiting status.
- Nov 16Trial initiationClinicalTrials.gov
Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM now recruiting.
- Oct 28Financial resultsSEC
VKTX 8-K (items 2.02, 9.01) reports results of operations.
- Oct 16Trial initiationClinicalTrials.gov
Phase 3 trial (SUNRISE 2) of oral VK2735 for weight management in Type 2 diabetes listed as not yet recruiting.
- Oct 16Trial initiationClinicalTrials.gov
Phase 3 trial NCT07868835 (SUNRISE 1) for oral VK2735 weight management listed as not yet recruiting.
- Oct 9Trial initiationClinicalTrials.gov
Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM updated to not yet recruiting.
- Oct 9Trial initiationClinicalTrials.gov
Phase 3 trial (SUNRISE 1) of oral VK2735 for weight management listed as not yet recruiting.
- Sep 29Trial initiationClinicalTrials.gov
Viking Therapeutics initiates Phase 1 trial of VK3019 in overweight and obese adults (NCT07846033).
- Sep 28DealSEC
8-K filing disclosing entry into material definitive agreement and creation of direct financial obligation (items 1.01, 2.03).
- Sep 25Securities offeringSEC
SEC Form 424B5 filed: prospectus supplement for securities offering.
- Sep 25Securities offeringSEC
VKTX filed Form 424B5 prospectus supplement for securities offering.
- Sep 24Trial initiationClinicalTrials.gov
Phase 1 trial NCT07838740 of VK2735 in obese adults without comorbidities status updated to recruiting.
- Sep 23Securities offeringSEC
Form 424B5 securities offering prospectus supplement filed.
- Sep 23Securities offeringSEC
424B5 prospectus supplement filed for securities offering.
- Sep 22OtherSEC
Viking Therapeutics files 8-K covering items 8.01 and 9.01.
- Aug 7Ownership changeSEC
SEC Form 4 insider transaction filing
- Jul 30Securities offeringSEC
Filed Form S-3ASR automatic shelf registration statement with SEC.
- Jul 29Financial resultsSEC
Viking Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.
- Jul 29Ownership changeSEC
SEC Form 4 filing reporting insider ownership change.
- Jul 29Ownership changeSEC
SEC Form 4 insider transaction filing.
Not financial advice — research and opinion only. Disclosures